Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can Viread be used for both HIV and Hep B?What antioxidants in berries boost lipitor's performance?Can St. John's Wort reduce the effectiveness of Birth Control?What are the benefits of non lipitor options?How does rofecoxib's selective cox 2 inhibition reduce gastric side effects?
See the DrugPatentWatch profile for Anktiva
What is Anktiva and how does it work? Anktiva, also known as GSK3320075, is a therapeutic cancer vaccine being developed by Agenus, Inc. (a subsidiary of Merck & Co.). It's designed to treat certain types of cancer, including bladder cancer. Unlike traditional chemotherapy or immunotherapy, Anktiva works by training the immune system to recognize and attack cancer cells. Clinical trials and efficacy Anktiva has shown promise in clinical trials for the treatment of bladder cancer. In a Phase 2 trial, patients with bladder cancer who received Anktiva demonstrated improved survival rates compared to those who received a placebo [1]. While the trial had its limitations, the results suggest that Anktiva may have therapeutic potential for bladder cancer patients. How does Anktiva treat bladder cancer specifically? Anktiva contains a recombinant protein called NY-ESO-1, which is a tumor antigen commonly found on bladder cancer cells. The vaccine is designed to stimulate an immune response against NY-ESO-1, allowing the body's immune system to target and eliminate bladder cancer cells [2]. By leveraging the immune system in this way, Anktiva may provide a more targeted and effective treatment for bladder cancer compared to traditional therapies. When will Anktiva be available, and will it be widely used? While Anktiva has shown promise in clinical trials, its availability and adoption depend on various factors, including regulatory approvals and market competition. It's also worth noting that Anktiva is still an investigational therapy and not yet approved for widespread use in the treatment of bladder cancer. References [1] ClinicalTrials.gov. (2022). A Study to Evaluate the Safety, Tolerability, and Efficacy of GSK3320075 in Participants With High-Grade Non-Muscle Invasive Bladder Cancer (GBMC 102). Retrieved from https://clinicaltrials.gov/ct2/show/NCT02178722 [2] Agenus, Inc. (n.d.). Anktiva (GSK3320075). Retrieved from https://www.agenusb.io/our-microbiome-and-oncolytic-viruses/anektiva-gsk3320075/
Other Questions About Anktiva :